Atlantic Lithium Limited (AIM:ALL, OTCQX:ALLIF, ASX:A11) has revealed a staged project development plan for its Ewoyaa lithium project in Ghana.
The plan focuses on optimised process flowsheet and mine throughput scenarios following the release of an increased mineral resource estimate in February 2023.
Corporate broker Liberum has repeated its buy and 56p a share price target on Atlantic Lithium Limited (AIM:ALL, OTCQX:ALLIF, ASX:A11) after it revealed a staged project development plan for its Ewoyaa lithium project in Ghana.
The new blueprint focuses on an optimised process flowsheet and mine throughput scenarios following the release of an increased mineral resource estimate in February 2023.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) is a ‘buy’ up to 524p, according to Peel Hunt in a note reacting to positive feedback from the US regulator following the completion of early-stage trials of the drug discovery group’s promising putative cancer treatment.
“Management commented that these trial data lay the groundwork for multiple routes to market and we believe this is an important milestone for the company, with Faron now able to reflect – with any future interaction with pharma – that their asset and plans align with FDA [Food & Drug Administration] thinking,” the broker told investors.
Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) has provided an update on the drilling activity at Rio Cravo Este (RCE) on the Tapir Block in the Llanos Basin of Colombia.
In a statement, Marshall Abbott, CEO of Arrow commented: "We are very encouraged by the initial production of RCE-4, the fifth well on the Tapir block, which has been completed in the C7-A and C7 Stringer zones with additional zones currently behind pipe. The RCE-4 well costs came in under budget and it was the quickest well drilled to date on the block."
Arecor Therapeutics PLC (AIM:AREC) said the first patient has been given a dose of the company's AT278 ultra-concentrated and rapid-acting insulin in a clinical trial for type two diabetes patients.
AT278 will be primarily targeted at type two diabetes patients, having already shown promise in those with type one, with the trial expected to be completed in the fourth quarter of this year, the AIM-listed biopharmaceutical company said on Wednesday.
Tap Global Group PLC (AQSE:TAP) said it has seen material increases since listing in registered users and revenue delivered via its crypto platform.
After reversing into Aquis-listed Quetzal Capital on 10 January, Tap said revenue in each of January and February was over three times that delivered in December, with the positive momentum carried through into March.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) said it received positive feedback and a green light from the US Food and Drug Administration (FDA) for further trials of cancer drug bexmarilimab as a monotherapy for solid tumours.
"FDA's feedback on the MATINS study gives Faron an excellent roadmap to plot out bexmarilimab's future strategy," said Marie-Louise Fjällskog, Faron’s chief medical officer.
Quantum Blockchain Technologies PLC (AIM:QBT), the AIM-listed cryptocurrency mining technology company, said it has published a research report on the financial performance of the world’s leading publicly-traded Bitcoin mining businesses.
Titled BTC 2022 Mining Industry: Main Listed Miners, the report’s key findings detail a surprising inverse relationship during 2022 between the Bitcoin price and the technical difficulty of mining successfully. As the price of Bitcoin fell, it became more difficult and expensive for miners to participate in the industry.
A Covid treatment that uses Graft Polymer (UK) PLC’s unique delivery system has been signed off as an over-the-counter drug in the US by the Food & Drug Administration. ArtemiC, developed and sold by MGC Pharma, uses GraftBio technology to get the active ingredients to the right place at the right time.